Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study

NCT02666430 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT02666430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02666430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study
Lead sponsor
Mylan Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
July 31, 2017
Enrollment
127 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus